The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement ...
Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...
The company anticipates preliminary data in the second half of 2026 for the ziftomenib and gilteritinib combination targeting ...
2d
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high- ...
Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at ASCO 2026: Rahway, New Jersey Wednesday, May 13, 2026, 11:00 Hrs [IST ...
Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the ...
Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...
European Commission approves Bristol Myers Squibb’s Sotyktu for the treatment of active psoriatic arthritis in adults: Princeton, New Jersey Monday, May 11, 2026, 15:00 Hrs [IST ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Bank of America Global Healthcare Conference 2026 May 12, 2026 11:00 AM EDTCompany ParticipantsWilliam Szablewski - Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results